Moderna stock rises after cancer vaccine reveal
The American company Moderna's stock rose by 62% to $102.01 following the announcement of a successful personalized cancer vaccine developed in collaboration with Merck. The vaccine, known as Intismeran Autogene, achieved the primary goal of the clinical trial when used in conjunction with the drug Keytruda, demonstrating a reduction in cancer recurrence and tumor spread compared to using Keytruda alone. These results mark the first successful late-stage development of a cancer treatment based on mRNA technology. The companies are expected to submit approval applications and potentially receive licensing by 2027. The trial findings represent an important step in the development of personalized cancer vaccines utilizing DNA technology, with ongoing studies to assess the treatment's impact on survival rates.
Notice: This Is an AI-Generated Summary
Comments (0)